Total Payments
$12,058
2024 Payments
$104.75
Companies
14
Transactions
44
Medicare Patients
4,074
Medicare Billing
$495,118
Payment Breakdown by Category
Research$10,920 (90.6%)
Food & Beverage$1,060 (8.8%)
Education$77.66 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $10,920 | 1 | 90.6% |
| Food and Beverage | $1,060 | 37 | 8.8% |
| Education | $77.66 | 6 | 0.6% |
Payments by Type
Research
$10,920
1 transactions
General
$1,138
43 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $10,920 | 1 | $0 (2020) |
| Novo Nordisk Inc | $311.44 | 5 | $0 (2017) |
| Allergan Inc. | $154.06 | 6 | $0 (2018) |
| Janssen Biotech, Inc. | $133.97 | 8 | $0 (2022) |
| UCB, Inc. | $109.54 | 1 | $0 (2021) |
| ABBVIE INC. | $96.52 | 5 | $0 (2024) |
| Gilead Sciences, Inc. | $95.84 | 5 | $0 (2023) |
| Edwards Lifesciences Corporation | $92.97 | 1 | $0 (2018) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $63.08 | 3 | $0 (2022) |
| Takeda Pharmaceuticals U.S.A., Inc. | $23.99 | 2 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $104.75 | 6 | ABBVIE INC. ($72.12) |
| 2023 | $56.14 | 2 | Gilead Sciences, Inc. ($31.74) |
| 2022 | $41.02 | 2 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($22.32) |
| 2021 | $256.05 | 10 | Janssen Biotech, Inc. ($115.27) |
| 2020 | $10,942 | 2 | Eli Lilly and Company ($10,920) |
| 2019 | $47.69 | 3 | Gilead Sciences, Inc. ($36.75) |
| 2018 | $124.05 | 4 | Edwards Lifesciences Corporation ($92.97) |
| 2017 | $486.09 | 15 | Novo Nordisk Inc ($311.44) |
All Payment Transactions
44 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/15/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $16.40 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 04/15/2024 | ABBVIE INC. | CREON (Drug), LINZESS | Food and Beverage | In-kind items and services | $16.94 | General |
| Category: ENDOCRINOLOGY | ||||||
| 04/08/2024 | ABBVIE INC. | CREON (Drug), LINZESS | Food and Beverage | In-kind items and services | $13.89 | General |
| Category: ENDOCRINOLOGY | ||||||
| 03/11/2024 | ABBVIE INC. | CREON (Drug), LINZESS | Food and Beverage | In-kind items and services | $13.21 | General |
| Category: ENDOCRINOLOGY | ||||||
| 02/22/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $28.08 | General |
| Category: GASTROENTEROLOGY | ||||||
| 02/21/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $16.23 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/16/2023 | AbbVie Inc. | LINZESS (Drug), CREON, VIBERZI | Food and Beverage | In-kind items and services | $24.40 | General |
| Category: GASTROENTEROLOGY | ||||||
| 05/24/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $31.74 | General |
| 08/01/2022 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $18.70 | General |
| Category: Immunology | ||||||
| 03/09/2022 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug) | Food and Beverage | In-kind items and services | $22.32 | General |
| Category: Gastroenterology | ||||||
| 10/23/2021 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $109.54 | General |
| Category: Immunology | ||||||
| 09/17/2021 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $14.16 | General |
| Category: Immunology | ||||||
| 07/16/2021 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $22.73 | General |
| Category: Immunology | ||||||
| 06/28/2021 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug) | Food and Beverage | In-kind items and services | $18.45 | General |
| Category: Gastroenterology | ||||||
| 06/10/2021 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $5.84 | General |
| Category: Immunology | ||||||
| 05/06/2021 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $24.38 | General |
| Category: Immunology | ||||||
| 04/26/2021 | Takeda Pharmaceuticals U.S.A., Inc. | — | Food and Beverage | In-kind items and services | $12.79 | General |
| 03/31/2021 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $22.37 | General |
| Category: Immunology | ||||||
| 03/04/2021 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $12.42 | General |
| Category: Immunology | ||||||
| 02/24/2021 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $13.37 | General |
| Category: Immunology | ||||||
| 09/29/2020 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | PLENVU (Drug) | Food and Beverage | In-kind items and services | $22.31 | General |
| Category: GASTROENTEROLOGY | ||||||
| 06/01/2020 | Eli Lilly and Company | — | — | Cash or cash equivalent | $10,920.00 | Research |
| Study: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE- CONTROLLED, TREAT-THROUGH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE | ||||||
| 12/03/2019 | Braintree Laboratories, Inc. | SUPREP BOWEL PREP (Drug) | Food and Beverage | In-kind items and services | $10.94 | General |
| Category: GI COLON PREP | ||||||
| 04/16/2019 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $18.82 | General |
| 03/26/2019 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $17.93 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE- CONTROLLED, TREAT-THROUGH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE | Eli Lilly and Company | $10,920 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 917 | 1,181 | $450,495 | $110,323 |
| 2022 | 12 | 1,092 | 1,546 | $736,020 | $140,885 |
| 2021 | 10 | 1,098 | 1,475 | $697,095 | $134,349 |
| 2020 | 13 | 967 | 1,294 | $554,054 | $109,561 |
Total Patients
4,074
Total Services
5,496
Medicare Billing
$495,118
Procedure Codes
46
All Medicare Procedures & Services
46 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 379 | 564 | $175,825 | $57,319 | 32.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 129 | 129 | $33,850 | $15,946 | 47.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 71 | 136 | $20,400 | $8,884 | 43.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 134 | 143 | $24,465 | $7,377 | 30.2% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 44 | 44 | $79,200 | $5,338 | 6.7% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 42 | 47 | $56,400 | $4,536 | 8.0% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 20 | 20 | $38,000 | $4,013 | 10.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 26 | 26 | $8,450 | $2,789 | 33.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 35 | 35 | $9,075 | $1,927 | 21.2% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 25 | 25 | $3,690 | $1,642 | 44.5% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2023 | 12 | 12 | $1,140 | $553.02 | 48.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 296 | 393 | $53,170 | $27,160 | 51.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 133 | 432 | $64,800 | $25,698 | 39.7% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 136 | 139 | $250,200 | $16,232 | 6.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 128 | 167 | $29,325 | $15,978 | 54.5% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 117 | 129 | $154,200 | $13,744 | 8.9% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 56 | 56 | $106,400 | $12,221 | 11.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 55 | 55 | $15,125 | $6,306 | 41.7% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 51 | 54 | $17,550 | $6,160 | 35.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 79 | 79 | $19,750 | $6,140 | 31.1% |
| 91120 | Test for tone and sensation of rectum and anus | Office | 2022 | 12 | 12 | $12,000 | $5,417 | 45.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 17 | 18 | $6,300 | $3,014 | 47.8% |
| 91122 | Study of rectum sensitivity and function | Office | 2022 | 12 | 12 | $7,200 | $2,815 | 39.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 308 | 437 | $58,995 | $32,355 | 54.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 127 | 323 | $48,450 | $19,721 | 40.7% |
About Dr. David Chua, MD
Dr. David Chua, MD is a Gastroenterology healthcare provider based in Oakbrook Terrace, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/10/2005. The National Provider Identifier (NPI) number assigned to this provider is 1346241585.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Chua, MD has received a total of $12,058 in payments from pharmaceutical and medical device companies, with $104.75 received in 2024. These payments were reported across 44 transactions from 14 companies. The most common payment nature is "" ($10,920).
As a Medicare-enrolled provider, Chua has provided services to 4,074 Medicare beneficiaries, totaling 5,496 services with total Medicare billing of $495,118. Data is available for 4 years (2020–2023), covering 46 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Oakbrook Terrace, IL
- Active Since 08/10/2005
- Last Updated 10/24/2011
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1346241585
Products in Payments
- Saxenda (Drug) $246.90
- LINZESS (Drug) $173.90
- STELARA (Biological) $133.97
- Cimzia (Drug) $109.54
- Edwards SAPIEN 3 Transcatheter Heart Valve (Device) $92.97
- CREON (Drug) $44.04
- TRULANCE (Drug) $40.77
- VIBERZI (Drug) $32.64
- PLENVU (Drug) $22.31
- XELJANZ (Drug) $16.40
- FARXIGA (Drug) $16.23
- (820) Cholbam (Drug) $13.12
- Dexilant (Drug) $11.20
- SUPREP BOWEL PREP (Drug) $10.94
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Oakbrook Terrace
Dr. Matthew Smith, M.d, M.D
Gastroenterology — Payments: $1,566
Gastroenterology $1,566
Dr. Jennie Ng, M.d, M.D
Gastroenterology — Payments: $1,273
Gastroenterology $1,273
Dr. Dhruva Tilwalli, Md, MD
Gastroenterology — Payments: $543.23
Gastroenterology $543.23
Dr. Stephen Grill, M.d, M.D
Gastroenterology
Gastroenterology